Somagenics, Inc. — Department of Health and Human Services SBIR Phase I: 200
Somagenics, Inc. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $287,788
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 200
- Solicitation
- PA14-071
- NAICS
- —
- Place of performance
- CA
- Period
- 2016-02-01 → 2017-10-31
Description
DESCRIPTION provided by applicant Quantification of gene expression in formalin fixed paraffin embedded FFPE tissue samples is important for the discovery and validation of cancer biomarkers for tumor classification and to assess progress during cancer treatment Because RT qPCR assays are very sensitive and sequence specific they are currently preferred for mRNA expression profiling in FFPE tissues as well as for validation of data obtained by other expression profiling methods such as microarrays and sequencing RNA seq However use of these methods to analyze FFPE samples is constrained by the RNA fragmentation that occurs in these samples and limits the sensitivity and reproducibility of these assays To overcome this problem we proposed a novel method for assaying mRNA fragments in FFPE samples called mR FQ mRNA Fragment Quantification In Preliminary Studies we developed a mR FQ prototype which can work with very short mRNA fragments of nt and demonstrated its superior sensitivity over the TaqMan RT qPCR method in quantifying two model mRNAs from FFPE samples We analyzed HER a breast cancer biomarker and GAPDH internal reference mRNAs in total RNA isolated from breast cancer and prostate cancer FFPE samples In Phase I we plan to i validate the mR FQ method using a larger number of target mRNAs and more FFPE samples ii further optimize mR FQ iii demonstrate that mR FQ reliably quantifies mRNAs in FFPE samples containing highly fragmented mRNAs that are not detectable by currently leading RT qPCR methods run in parallel iv determine the maximum mRNA fragmentation level detectable by mR FQ In Phase II we will move towards commercialization by designing mR FQ assays for BC biomarker candidates and validating them on FFPE samples having a wide range of RNA fragmentation levels with focus on currently unusable samples those containing highly fragmented RNA that cannot be assayed by standard RT qPCR methods mR FQ and RNA seq analyses will be compared and we expect that mR FQ will be able to validate RNA seq results since both methods can work with highly fragmented RNA This will allow researchers to include a wider range of FFPE samples into retrospective studies for the development and validation of improved breast as well as other types of cancer diagnostics and treatment prognostics PUBLIC HEALTH RELEVANCE This project develops new technology for studying gene expression archived tissue specimens from cancer patients We plan to use it to develop better biomarkers for breast cancer the most common cancer among women About women were diagnosed and over died from the disease last year in the US alone The goal of this grant application is to develop a method for quantitation of fragmented mRNAs from standard histology specimens FFPE blocks that will provide superior sensitivity and accuracy at a reasonable cost to facilitate research in and diagnosis of breast cancer as well as treatment prognosis